Literature DB >> 10521265

Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation.

G A Nicolaes1, B O Villoutreix, B Dahlbäck.   

Abstract

Coagulation factor V (FV) circulates in two forms, FV1 and FV2, having slightly different molecular masses and phospholipid-binding properties. The aim was to determine whether this heterogeneity is due to the degree of glycosylation of Asn(2181). FVa1 and FVa2 were isolated and digested with endoglycosidase PNGase F. As judged by Western blotting, the FVa2 light chain contained two N-linked carbohydrates, whereas FVa1 contained three. Wild-type FV and three mutants, Asn(2181)Gln, Ser(2183)Thr, and Ser(2183)Ala, were expressed in COS1 cells, activated by thrombin, and analyzed by Western blotting. Wild-type FVa contained the 71 kDa-74 kDa doublet, whereas the Asn(2181)Gln and Ser(2183)Ala mutants contained only the 71 kDa light chain. In contrast, the Ser(2183)Thr mutant gave a 74 kDa light chain. This demonstrated that the third position in the Asn-X-Ser/Thr consensus affects glycosylation efficiency, Thr being associated with a higher degree of glycosylation than Ser. The Ser(2183)Thr mutant FVa was functionally indistinguishable from plasma-purified FVa1, whereas Asn(2181)Gln and Ser(2183)Ala mutants behaved like FVa2. Thus, the carbohydrate at Asn(2181) impaired the interaction between FVa and the phospholipid membrane, an interpretation consistent with a structural analysis of a three-dimensional model of the C2 domain and the position of a proposed phospholipid-binding site. In conclusion, we show that the FV1-FV2 heterogeneity is caused by differential glycosylation of Asn(2181) related to the presence of a Ser rather than a Thr at the third position in the consensus sequence of glycosylation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10521265     DOI: 10.1021/bi991165r

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  Novel role for galectin-8 protein as mediator of coagulation factor V endocytosis by megakaryocytes.

Authors:  Claudia Zappelli; Carmen van der Zwaan; Daphne C Thijssen-Timmer; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

2.  Inhibition of thrombin formation by active site mutated (S360A) activated protein C.

Authors:  Gerry A F Nicolaes; Paul E Bock; Kenneth Segers; Karin C A A Wildhagen; Björn Dahlbäck; Jan Rosing
Journal:  J Biol Chem       Date:  2010-05-18       Impact factor: 5.157

3.  Factor VIII C1 domain spikes 2092-2093 and 2158-2159 comprise regions that modulate cofactor function and cellular uptake.

Authors:  Esther Bloem; Maartje van den Biggelaar; Aleksandra Wroblewska; Jan Voorberg; Johan H Faber; Marianne Kjalke; Henning R Stennicke; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2013-09-05       Impact factor: 5.157

4.  Mapping N-linked glycosylation sites in the secretome and whole cells of Aspergillus niger using hydrazide chemistry and mass spectrometry.

Authors:  Lu Wang; Uma K Aryal; Ziyu Dai; Alisa C Mason; Matthew E Monroe; Zhi-Xin Tian; Jian-Ying Zhou; Dian Su; Karl K Weitz; Tao Liu; David G Camp; Richard D Smith; Scott E Baker; Wei-Jun Qian
Journal:  J Proteome Res       Date:  2011-12-02       Impact factor: 4.466

5.  A phosphatidylserine binding site in factor Va C1 domain regulates both assembly and activity of the prothrombinase complex.

Authors:  Rinku Majumder; Mary Ann Quinn-Allen; William H Kane; Barry R Lentz
Journal:  Blood       Date:  2008-06-27       Impact factor: 22.113

6.  α(1,3)-Fucosyltransferases FUT4 and FUT7 control murine susceptibility to thrombosis.

Authors:  Huili Wang; Maria Morales-Levy; Jason Rose; Lantz C Mackey; Peter Bodary; Daniel Eitzman; Jonathon W Homeister
Journal:  Am J Pathol       Date:  2013-04-02       Impact factor: 4.307

7.  Theoretical and experimental study of the D2194G mutation in the C2 domain of coagulation factor V.

Authors:  M A Miteva; J M Brugge; J Rosing; G A F Nicolaes; B O Villoutreix
Journal:  Biophys J       Date:  2004-01       Impact factor: 4.033

8.  Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C.

Authors:  Andrew J Gale; Xiao Xu; Jean-Luc Pellequer; Elizabeth D Getzoff; John H Griffin
Journal:  Protein Sci       Date:  2002-09       Impact factor: 6.725

9.  Comprehensive N- and O-glycosylation mapping of human coagulation factor V.

Authors:  Cheng Ma; Ding Liu; Dong Li; Junping Zhang; Xiao-Qian Xu; He Zhu; Xiu-Feng Wan; Carol H Miao; Barbara A Konkle; Philip Onigman; Weidong Xiao; Lei Li
Journal:  J Thromb Haemost       Date:  2020-06-14       Impact factor: 5.824

10.  ptFVa (Pseudonaja Textilis Venom-Derived Factor Va) Retains Structural Integrity Following Proteolysis by Activated Protein C.

Authors:  Mark Schreuder; Xiaosong Liu; Ka Lei Cheung; Pieter H Reitsma; Gerry A F Nicolaes; Mettine H A Bos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-06-24       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.